Results 161 to 170 of about 129,762 (268)

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Rodent monocyte‐derived macrophages do not express CD163: Comparative analysis using macrophages from living boreoeutherians

Developmental Dynamics, EarlyView.
Abstract Background CD163 is a scavenger receptor predominantly expressed on the surfaces of macrophages in various mammalian species and is a marker of anti‐inflammatory (M2‐like) macrophages. High density of CD163‐positive tumor‐associated macrophages (TAMs) is associated with worse prognosis in various patient tumors.
Yoichi Saito, Yukio Fujiwara, Yasuka L. Yamaguchi, Satomi S. Tanaka, Kyoko Miura, Yoshiyuki Hizukuri, Kyoko Yamashiro, Yasuhiro Hayashi, Yuta Nakashima, Yoshihiro Komohara   +9 more
wiley   +1 more source

A Comparative Bibliometric Analysis of Pediatric Interstitial Lung Disease Treatment: Global Trends, Advances, and Future Directions (2004-2024). [PDF]

Pediatr Pulmonol
Ma L, Yang L, Su S, Chen W.
europepmc   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Chronic Productive Cough in an Immunosuppressed Patient due to Biologics: A Rare Case of <i>Bordetella bronchiseptica</i> Pulmonary Infection. [PDF]

Respirol Case Rep
Banerjee D, Ayaz E, Hudson A, Trainor E, Vijayakumar B, Bandara H.   +5 more
europepmc   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi, Gabriele Novello, Francesca Bursi, Anna Caretti, Noemi Furlotti, Ross Arena, Paola Argiento, Julio Núñez, Antoni Bayes‐Genis, Marco Metra   +9 more
wiley   +1 more source

Patient-reported experience measure (PREM) for patients with interstitial lung disease (ILD): modification of a pre-existing measure. [PDF]

BMJ Open Respir Res
Mandizha J, Crook C, Lanario J, Davies R, Duckworth A, Almond HP, Lines S, Gibbons M, Scotton C, Russell AM.   +9 more
europepmc   +1 more source

Increased calcification by erythrophagocytosis in aortic valvular interstitial cells

ESC Heart Failure, Volume 12, Issue 2, Page 1469-1473, April 2025.
Abstract Background Calcific aortic valve disease (CAVD) progresses over time to severe aortic stenosis and eventually heart failure. Recent evidence indicates that intraleaflet haemorrhage (ILH) strongly promotes CAVD progression. However, it remains poorly understood how it mechanistically contributes to valvular calcification.
Zihan Qin, Magnus Bäck, Anders Franco‐Cereceda, Sven‐Christian Pawelzik   +3 more
wiley   +1 more source

Gender-age-physiology stage and body mass index are useful predictors of nintedanib discontinuation and prognosis in patients with idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases. [PDF]

BMC Pulm Med
Yazaki K, Matsuyama M, Satoh H, Miyazaki K, Arai N, Ishii Y, Endo T, Kaburagi T, Kawakami T, Iijima H, Motegi T, Hayashi S, Kikuchi N, Sakamoto T, Hizawa N.   +14 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source